|Description||Masitinib is an orally bioavailable and multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity.|
|B0084-077384||250 mg||$198||In stock|
|B0084-077384||500 mg||$348||In stock|
|Synonyms||AB-1010; AB 1010; AB1010; Masitinib. Brand name: Kinavet; Masivet.|
|Current Developer||AB Science|
Imatinib (INN), marketed by Novartis as Gleevec (Canada, South Africa and the USA) or Glivec (Australia, Europe and Latin America), and sometimes referred to by...
Amuvatinib, also known as MP-470, is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. MP470 inhibits activities of other ...
Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the...
Flumatinib is a multi-kinase inhibitor of c-Abl, PDGFRβ and c-Kit with IC50 values of 1.2 nM, 307.6 nM and 2662 nM respectively. It can predominantly inhibit th...
Sitravatinib, a new inhibitor of tyrosine kinase, has been studied to have effective in inhibiting tyrosine kinases receptors involved in driving sarcoma cell g...
Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more...
BLU-285 is a potent and selective inhibitor of exon 17 mutant KIT (IC50= 0.27 nM for KIT D816V). BLU-285 showed dose-dependent, robust anti-tumor efficacy in a ...
Masitinib mesylate is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.